ENPP3

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Pharmaceutical, Health, Oncology, CD20, NSCLC, Cancer, J&J, Immune system, Alanine transaminase, Autoimmune disease, Research, ENPP3, Investment, ALT, PSMA, Cell, Antibody, Autoimmune hepatitis, Safety, Telephone, Vir, Lymphoid leukemia, Rash, Patient, PSA, RECIST, CLDN6, Diagnosis, Prostate-specific antigen, G&A, Workforce, CD28, Prostate cancer, Pharmaceutical industry

Both programs entered Phase 1 clinical development during the fourth quarter of 2023, and Xencor received $20 million in development milestones.

Key Points: 
  • Both programs entered Phase 1 clinical development during the fourth quarter of 2023, and Xencor received $20 million in development milestones.
  • In the fourth quarter of 2023, Xencor completed enrollment in subcutaneous dose-escalation cohorts of a Phase 1 study evaluating plamotamab.
  • Financial Results for the Fourth Quarter and Full Year Ended December 31, 2023
    Cash, cash equivalents, and marketable debt securities totaled $697.4 million as of December 31, 2023, compared to $584.5 million on December 31, 2022.
  • Total revenue for the fourth quarter ended December 31, 2023 was $44.7 million compared to $21.6 million for the same period in 2022.

Xencor Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CLDN3, Ovarian cancer, CD28, Telephone, STEAP1, OMERS, CLDN4, Sale, Vir, ESMO, Amgen, Cytokine, Gilead Sciences, Antibody, Part, Safety, Cancer, Investment, Patient, Congress, G&A, Prostate cancer, CTA, ENPP3, CLDN6, Liver disease, Genentech, European Society for Medical Oncology, CLDN9, Tafasitamab, IND, CD3, Colorectal cancer, R, Environment, Ravulizumab, Lung cancer, PARP, Vaccine, Pharmaceutical industry, Medical imaging, Rare-earth element, Cryptocurrency, Omeros, Janssen, MorphoSys, Alexion, Astellas Pharma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a review of recent business and clinical highlights.
  • Total revenue for the third quarter ended September 30, 2023 was $59.2 million, compared to $27.3 million for the same period in 2022.
  • Decreased net loss in the third quarter of 2023 compared to 2022 is primarily due to additional income earned.
  • ET (1:30 p.m. PT) to discuss the third quarter 2023 financial results and provide a corporate update.

Xencor Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ICOS, AACR, CD28, European Alliance of Associations for Rheumatology, Cancer, ENPP3, American Association for Cancer Research, Janssen, TACSTD2, NMOSD, Research, CLDN6, Part, Genentech, Antibody, AstraZeneca, CEACAM5, ASCO, Congress, Patient, STEAP1, Ipilimumab, Colorectal cancer, Vir, EULAR, Cytokine, PD-1, Neuromyelitis optica spectrum disorder, Ovarian cancer, European Alliance, IND, Tumor microenvironment, Roche, Vaccine, Pharmaceutical industry, Cryptocurrency, Video game, EU, MorphoSys, Astellas Pharma, Rheumatology, Alexion, Ravulizumab

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.
  • In the first quarter of 2023, Xencor earned $10.5 million of royalty revenue from Alexion on net sales of Ultomiris.
  • Revenues for the first quarter ended March 31, 2023 were $19.0 million, compared to $85.5 million for the same period in 2022.
  • ET (1:30 p.m. PT) to discuss the first quarter 2023 financial results and provide a corporate update.

Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, AACR, Half-life, CD28, CD3, CD86, Cancer, ENPP3, American Association for Cancer Research, TACSTD2, Antibody, CEACAM5, TCR, STEAP1, CD80, Cytokine, Tumor microenvironment, Vaccine

The data were presented in a poster titled “Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors” (Abstract 2983) at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

Key Points: 
  • The data were presented in a poster titled “Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors” (Abstract 2983) at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.
  • T cells in the tumor microenvironment require engagement of both their T cell receptor (TCR) and their co-stimulatory receptors, like CD28, to achieve full activation.
  • Xencor has developed a modular XmAb® bispecific antibody platform that allows for the rapid generation of drug candidates that co-stimulate CD28 only in the presence of tumor cells and TCR engagement.
  • “We are leveraging the plug-and-play nature of our XmAb bispecific antibody platforms to generate and explore additional CD28 drug candidates against a broader universe of solid tumor targets.”

Xencor Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, ENPP3, Pembrolizumab, CD28, Caris, Cancer, RCC, Immune system, Cowen, Psoriasis, Laboratory, IND, CLDN6, Investment, Patient, Biology, R, Janssen, Neoplasm, CD20, Renal cell carcinoma, Bispecific monoclonal antibody, Therapeutic index, Sale, Antibody, CD3, Cytokine, Protein engineering, Novartis, Kidney cancer, Vir, G&A, Prostate, Atopic dermatitis, Vaccine, Cryptocurrency, Online shopping, Barclays, Regulatory T cell, Astellas Pharma, MorphoSys, Alexion

Financial Results for the Fourth Quarter and Full Year Ended December 31, 2022

Key Points: 
  • Financial Results for the Fourth Quarter and Full Year Ended December 31, 2022
    Cash, cash equivalents, receivables and marketable debt securities totaled $613.5 million as of December 31, 2022, compared to $664.1 million on December 31, 2021.
  • Total revenue for the fourth quarter ended December 31, 2022 was $21.6 million compared to $154.0 million for the same period in 2021.
  • General and administrative (G&A) expenses for the fourth quarter ended December 31, 2022 were $12.8 million compared to $11.4 million for the same period in 2021.
  • ET (1:30 p.m. PT) to discuss the full year 2022 financial results and provide a corporate update.

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IND, Degenerative disease, Autoimmune disease, Janssen, Hoffmann-La Roche, Ipilimumab, Lymphoma, Ovarian cancer, Monoclonal antibody, Janssen Biotech, Bispecific monoclonal antibody, CD28, Cytokine, ICOS, Tumor microenvironment, Psoriasis, ENPP3, RCC, Biology, CLDN6, NK, Immune system, Protein engineering, Ligand, Patient, Genentech, CD3, Atopic dermatitis, Research, Cancer, Claudin, CLDN9, Antibody, Lenalidomide, MCRPC, Vaccine, Pharmaceutical industry, Medicine, Medical imaging, Regulatory T cell

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.
  • “We are building on this momentum in 2023, progressing our clinical portfolio internally and with our co-development partners, including four bispecific antibody programs targeting solid tumors.
  • Xencor plans to:
    Continue enrolling patients into the Phase 1b, multiple-ascending dose study in patients with atopic dermatitis and psoriasis.
  • Xencor ended the fourth quarter of 2022 with unaudited cash, cash equivalents, receivables and marketable debt securities totaling approximately $610 million.

Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, TCR, U.S. Securities and Exchange Commission, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Renal cell carcinoma, Therapy, Investor, Therapeutic index, CD3, Cytokine, Degenerative disease, MCRPC, NASDAQ, Antibody, Patient, Security (finance), Annual report, Immunotherapy, Technology, Private Securities Litigation Reform Act, RCC, Form 10-K, Trial of the century, Company, Immune system, IL18, Society, PD-1, Kidney cancer, Prostate cancer, Forward-looking statement, ENPP3, Poster, Vaccine, Medical imaging, Cancer

In the poster hall, odd numbered posters will be displayed on Thursday, November 10, and even numbered posters will be displayed on Friday, November 11.

Key Points: 
  • In the poster hall, odd numbered posters will be displayed on Thursday, November 10, and even numbered posters will be displayed on Friday, November 11.
  • Posters will be archived under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com .
  • Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases.
  • More than 20 candidates engineered with Xencor's XmAb technology are in clinical development, and three XmAb medicines are marketed by partners.

Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones

Retrieved on: 
Tuesday, January 11, 2022
Technology, Medical Devices, Hospitals, Nanotechnology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Forward-looking statement, Patient, Research, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Technology, Annual report, Janssen Pharmaceuticals, Lymphoma, Biology, Private Securities Litigation Reform Act, Form 10-K, Cytokine, Johnson & Johnson, CD28, Protein, NASDAQ, Tafasitamab, IND, ENPP3, U.S. Securities and Exchange Commission, Lenalidomide, Half-life, Ligand, Protein engineering, CD3, RCC, Therapy, Cancer, Engineering, Security (finance), DLBCL, Degenerative disease, Vaccine, Pharmaceutical industry, Renewable energy, MCRPC

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2022 corporate priorities and anticipated clinical development and research milestones.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2022 corporate priorities and anticipated clinical development and research milestones.
  • Present initial data from the Phase 2 study in mCRPC, in the second half of 2022.
  • Xencor plans to:
    Initiate a Phase 1 study evaluating XmAb819 in patients with RCC in the first half of 2022.
  • Xencor plans to:
    Submit an IND application in the first half of 2022, and initiate a Phase 1 study in patients with advanced solid tumors in the second half of 2022.

Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 17, 2020
Health, Pharmaceutical, Enzymes, Autotaxin, Phosphodiesterase, Nucleotide pyrophosphatase/phosphodiesterase, Alkylglycerophosphoethanolamine phosphodiesterase, Phospholipase, ENPP3, Ectonucleotide pyrophosphatase/phosphodiesterase 1

The "Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) is an enzyme encoded by the ENPP2 gene.
  • Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) pipeline Target constitutes close to 17 molecules.
  • The latest report Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.